These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25622007)

  • 1. Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
    Yokoyama H; Sawada J; Katoh S; Matsuno K; Ogo N; Ishikawa Y; Hashimoto H; Fujii S; Asai A
    ACS Chem Biol; 2015 Apr; 10(4):1128-36. PubMed ID: 25622007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.
    Kaan HY; Ulaganathan V; Hackney DD; Kozielski F
    Biochem J; 2009 Dec; 425(1):55-60. PubMed ID: 19793049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Biphenyl-Type Inhibitors Targeting the Eg5 α4/α6 Allosteric Pocket.
    Gao C; Lowndes NF; Eriksson LA
    ACS Omega; 2017 May; 2(5):1836-1849. PubMed ID: 30023646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into a unique inhibitor binding pocket in kinesin spindle protein.
    Ulaganathan V; Talapatra SK; Rath O; Pannifer A; Hackney DD; Kozielski F
    J Am Chem Soc; 2013 Feb; 135(6):2263-72. PubMed ID: 23305346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
    Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
    Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
    Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
    Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
    Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
    Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
    Makala H; Ulaganathan V
    J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the intermediate states of ADP-ATP exchange: a simulation study on Eg5.
    Zhang W
    J Phys Chem B; 2011 Feb; 115(5):784-95. PubMed ID: 21192710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleotide-dependent movements of the kinesin motor domain predicted by simulated annealing.
    Wriggers W; Schulten K
    Biophys J; 1998 Aug; 75(2):646-61. PubMed ID: 9675167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP.
    Rickert KW; Schaber M; Torrent M; Neilson LA; Tasber ES; Garbaccio R; Coleman PJ; Harvey D; Zhang Y; Yang Y; Marshall G; Lee L; Walsh ES; Hamilton K; Buser CA
    Arch Biochem Biophys; 2008 Jan; 469(2):220-31. PubMed ID: 17999913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
    Maliga Z; Kapoor TM; Mitchison TJ
    Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
    Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
    Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
    Talapatra SK; Tham CL; Guglielmi P; Cirilli R; Chandrasekaran B; Karpoormath R; Carradori S; Kozielski F
    Eur J Med Chem; 2018 Aug; 156():641-651. PubMed ID: 30031975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinesin-5 allosteric inhibitors uncouple the dynamics of nucleotide, microtubule, and neck-linker binding sites.
    Scarabelli G; Grant BJ
    Biophys J; 2014 Nov; 107(9):2204-13. PubMed ID: 25418105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Snapshots" of ispinesib-induced conformational changes in the mitotic kinesin Eg5.
    Kaan HY; Major J; Tkocz K; Kozielski F; Rosenfeld SS
    J Biol Chem; 2013 Jun; 288(25):18588-98. PubMed ID: 23658017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
    Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
    J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding patterns of inhibitors to different pockets of kinesin Eg5.
    Jia N; Zhang B; Huo Z; Qin J; Ji Q; Geng Y
    Arch Biochem Biophys; 2024 Jun; 756():109998. PubMed ID: 38641233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
    Sun L; Sun X; Xie S; Yu H; Zhong D
    Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
    DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
    Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.